ArticleJournal of thoracic disease2026
Post-cardiotomy right ventricular failure requiring intraoperative right ventricular assist device placement: real-world experiences.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-cardiotomy right ventricular failure (RVF) may be refractory to conservative measures and temporary mechanical circulatory support may be indicated. Little data exists regarding intraoperative post-cardiotomy RVF requiring concomitant right ventricular assist device (RVAD) placement. We undertook this study to analyze the impact of intraoperative RVF requiring concomitant RVAD placement. Methods: This is a retrospective analysis of consecutive patients from 2018 to 2023 who experienced post-cardiotomy RVF and received intraoperative RVAD support. The primary outcome was patient survival to discharge. All patients were included in analysis, and none were excluded. Results: From 2018 to 2023, 23 patients experienced intraoperative post-cardiotomy RVF and underwent concomitant RVAD placement. During this time frame, a total of 9,268 cardiac surgeries were performed at Baylor Scott & White Research Institute. Those who underwent concomitant RVAD placement had a median follow-up time of 152 [interquartile range (IQR), 52-418] days. Fifty-six percent (13/23) were male, and the median age was 67 (IQR, 60-72) years. Eight patients received isolated RVAD placement, 14 received RVAD and left ventricular assist device (LVAD), and 1 received RVAD with venoarterial (VA)-extracorporeal membrane oxygenation (ECMO) configuration. All RVADs consisted of the Protek Duo (LivaNova) cannula connected to an ECMO circuit. Two patients required two rounds of RVAD support. The median duration of RVAD support was 8 (IQR, 7-17) days. Survival to discharge was 78.3% (18/23), and the median length of stay was 30 (IQR, 20-41) days. Of the five in-hospital mortalities, 60% (3/5) of patients were unable to be weaned from extracorporeal life support. Overall patient survival at 30-day was 78.3% (18/23). In patients successfully weaned from RVAD support, survival to discharge and 30-day survival were 90%. Conclusions: Concomitant RVAD placement appears to be a helpful treatment strategy for intraoperative RVF. Patients who are successfully weaned from RVAD support have acceptable short-term outcomes following discontinuation of support, although further research is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.